Don't miss

Replay


LATEST SHOWS

EYE ON AFRICA

Kenya’s opposition leader to take poll dispute to Supreme Court

Read more

MEDIAWATCH

Trump's 'unprecedented transgression'

Read more

THE DEBATE

US racial tension - How far should freedom of speech be allowed to go?

Read more

THE DEBATE

Burkina Faso attack: How to restore security in the Sahel region?

Read more

THE DEBATE

India and Pakistan mark 70 years of independence: Can the two countries ever reconcile?

Read more

ACCESS ASIA

India: Cows at heart of political debate

Read more

IN THE PAPERS

Trump again blames both sides for Charlottesville violence

Read more

IN THE PAPERS

'Macron: The shadow of a doubt'

Read more

BUSINESS DAILY

Talks to begin on revamping NAFTA trade deal

Read more

Business

EU regulators raid drugmakers' offices

Text by NEWS WIRES

Latest update : 2009-10-06

The European Commission says it has begun "surprise inspections" at the premises of European pharmaceutical giants over suspected violations of competition rules. Drugmakers are suspected of seeking to delay the launch of cheaper generic products.

AFP - Investigators carried out raids on European pharmaceutical giants on Tuesday over suspected competition violations, the European Commission said in a statement.
   
Brussels "can confirm that on October 6 commission officials started surprise inspections at the premises of certain companies active in the pharmaceutical industry," the statement said.
   
France's Sanofi-Aventis was one of those raided, a company spokesman told AFP. "Sanofi is going to cooperate with the commission," he added.
   
Belgium's UCB and Solvay, Britain's AstraZeneca, France's Servier and Germany's Bayer and Merck each said they were not targeted.
   
Officials accompanied by national inspectors were seeking evidence of "restrictive business practices and/or the abuse of a dominant market position," the commission, which polices competition in the EU, added.
   
Regulators stepped up a sector-wide probe launched in January 2008 with an investigation announced in July into the relationship between companies that patent their products as brand-named medicine, as well as their ties with generic drug producers.
   
Then, the commission said that "unilateral behaviour" by French pharmaceutical maker Les Laboratoires Servier might have hindered the entry into EU markets of generic perindopril, a cardio-vascular medicine first developed by the company.
   
The commission did not detail the companies or countries involved, and stressed that such steps follow no fixed deadlines.
 

Date created : 2009-10-06

COMMENT(S)